{
  "pages": [
    {
      "index": 0,
      "markdown": "# $\\rightarrow$ atna \n\n## MEDICARE FORM\n\nRiabni ${ }^{\\circledR}$ (rituximab-arrx), Rituxan ${ }^{\\circledR}$ (rituximab), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs) Medication Precertification Request Page 1 of 5\n(All fields must be completed and legible for precertification review.)\n\nFor Medicare Advantage Part B: For other lines of business: Please use commercial form.\n\nNote: Riabni and Rituxan are nonpreferred. The preferred biosimilar products are Ruxience and Truxima. For rheumatoid arthritis, all Rituxan and biosimilar products are non-preferred.\n\nWould you like to use electronic prior authorization? Consider using Availity, our electronic prior authorization portal. Learn more about Availity from the links in the table below.\n\nFor phone or fax requests, refer to the table below for routing information. To determine which box to use, refer to the patient's Aetna ID card. State specific special needs and Medicare-Medicaid Plans may be designated on the front of the ID card or in the website URL on the back of the card. If you don't see your specific plan listed, call the number on the back of the member's ID card to confirm routing information.\n\nFor Aetna Medicare Advantage and Allina Health Aetna Medicare members send request to:\nPhone: 1-866-503-0857 (TTY: 711)\nFax: $\\quad 1-844-268-7263$\nAvaility: https://www.aetna.com/health-care-professionals/resource-center/availity.html\nFor Aetna Medicare Advantage Virginia Dual Eligible Special Needs Plans (HMO D-SNP) send request to:\nPhone: $\\quad 1-855-463-0933$\nFax: $\\quad 1-833-280-5224$\nAvaility: https://www.aetnabetterhealth.com/virginia-hmosnp/providers/portal\nFor Aetna Assure Premier Plus Medicare Advantage New Jersey Dual Eligible Special Needs Plans (HMO D-SNP) send request to:\nPhone: $\\quad 1-844-362-0934$\nFax: $\\quad 1-833-322-0034$\nAvaility: https://www.aetnabetterhealth.com/new-jersey-hmosnp/providers/portal.html\nFor Aetna Better Health of Illinois Premier Medicare Medicaid Plan (MMP) send request to:\nPhone: $\\quad 1-866-600-2139$\nFAX: $\\quad 1-855-320-8445$\nAvaility: https://www.aetnabetterhealth.com/illinois/providers/portal\nFor Aetna Better Health of Ohio Premier Medicare Medicaid Plan (MMP) send request to:\nPhone: $\\quad 1-855-364-0974$\nFax: $\\quad 1-855-734-9389$\nAvaility: https://www.aetnabetterhealth.com/ohio/providers/portal\nFor Aetna Better Health of Michigan Premier Medicare Medicaid Plan (MMP) send request to:\nPhone: $\\quad 1-855-676-5772$\nFax: $\\quad 1-844-241-2495$\nAvaility: https://www.aetnabetterhealth.com/michigan/providers/portal.html",
      "images": [],
      "dimensions": {
        "dpi": 200,
        "height": 2200,
        "width": 1700
      }
    },
    {
      "index": 1,
      "markdown": "# MEDICARE FORM\nRiabni\u00ae (rituximab-arrx),\nRituxan\u00ae (rituximab), Ruxience\n(rituximab-pvvr), Truxima (rituximab-abbs)\nMedication Precertification Request\nPage 2 of 5\n(All fields must be completed and return both pages for precertification review.)\nFor Medicare Advantage Part B:\nFor other lines of business:\nPlease use commercial form.\nNote: Riabni and Rituxan are non-\npreferred. The preferred biosimilar\nproducts are Ruxience and Truxima.\nFor rheumatoid arthritis, all Rituxan and\nbiosimilar products are non-preferred.\nPlease indicate: \u2610 Start of treatment, start date: _____/____/_____ \u2610 Continuation of therapy, date of last treatment: _____/____/____/_____\nPrecertification Requested By: Phone: Fax: ______________________________\n\nA. PATIENT INFORMATION\nFirst Name: Last Name: DOB:\nAddress: City: State: ZIP:\nHome Phone: Work Phone: Cell Phone: E-mail:\nCurrent Weight: ______ lbs or ______ kgs Height: ______ inches or ______ cms Allergies:\n\nB. INSURANCE INFORMATION\nMember ID #: Does patient have other coverage? \u2610 Yes \u2610 No\nGroup #: If yes, provide ID#: Carrier Name: ______________________________\nInsured: Insured: ______________________________ Insured: ______________________________\n\nC. PRESCHIBER INFORMATION\nFirst Name: Last Name: (Check one): \u2610 M.D. \u2610 D.O. \u2610 N.P. \u2610 P.A.\nAddress: City: State: ZIP:\nPhone: Fax: St Lic #: NPI #: DEA #: UPIN:\nProvider Email: Office Contact Name: Phone:\n\nD. DISPENSING PROVIDER/ADMINISTRATION INFORMATION\nPlace of Administration: Dispensing Provider/Pharmacy:\n\u2610 Self-administered \u2610 Physician's Office \u2610 Home \u2610 Outpatient Dialysis Center \u2610 Physician's Office\n\u2610 Outpatient Infusion Center Name: \u2610 Retail Pharmacy \u2610 Specialty Pharmacy\n\u2610 Home Infusion Center Phone: \u2610 Mail Order \u2610 Other: ______________________________\nAgency Name: Name: ______________________________\n\u2610 Administration code(s) (CPT): Address: Address: ______________________________\nCity: State: ZIP: ______________________________\nPhone: Fax: Phone: Fax: ______________________________\nTIN: PIN: NPI: NPI: ______________________________\nE. PRODUCT INFORMATION\nRequest is for: \u2610 Riabni (rituximab-arrx) \u2610 Rituxan (rituximab) \u2610 Ruxience (rituximab-pvvr) \u2610 Truxima (rituximab-abbs)\nDose: Directions for Use: HCPCS Code: ______________________________\nF. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other any other where applicable (*):\nPrimary ICD Code: \u2610 Other ICD Code: ______________________________\n\nG. CLINICAL INFORMATION - Required clinical information must be completed for ALL precertification requests.\nFor Initiation Requests (clinical documentation required for all requests):\nNote: Riabni and Rituxan are non-preferred. Ruxience and Truxima are the preferred biosimilars for most indications.\nFor rheumatoid arthritis, all Rituxan and biosimilar products are non-preferred. Inflectra, Renflexis and Simponi Aria are preferred for MA plans.\nEnbrel, Humira, Idacio, Rinvoq, Tyenne SC and Xeljanz/Xeljanz XR are preferred for MAPD plans.\n\u2610 Yes \u2610 No Has the patient had prior therapy with the requested product within the last 365 days?\n\u2610 No Has the patient had a trial and failure of any of the following rituximab biosimilars? (If yes, select all that apply)\n\u2610 \u2610 Ruxience (rituximab-pvvr) \u2610 Truxima (rituximab-abbs)\n\u2610 When was the member's trial and failure of the preferred drug? ______________________________\n\u2610 Please describe the nature of the failure of the preferred drug ______________________________\n\u2610 No Has the patient had an adverse reaction to any of the following rituximab biosimilars? (If yes, select all that apply)\n\u2610 \u2610 Ruxience (rituximab-pvvr) \u2610 Truxima (rituximab-abbs)\n\u2610 When was the member's adverse reaction to the preferred drug? ______________________________\n\u2610 Please describe the nature of the adverse reaction to the preferred drug ______________________________\nPlease explain if there are any contraindications or other medical reason(s) that the patient cannot use any of the following preferred biosimilar products when\nindicated for the patient's diagnosis? (select all that apply)\n\u2610 Ruxience (rituximab-pvvr) \u2610 Truxima (rituximab-abbs)\n\nContinued on next page",
      "images": [],
      "dimensions": {
        "dpi": 200,
        "height": 2200,
        "width": 1700
      }
    },
    {
      "index": 2,
      "markdown": "# MEDICARE FORM\nRiabni\u00ae (rituximab-arrx),\nRituxan\u00ae (rituximab), Ruxience\n(rituximab-pvvr), Truxima (rituximab-abbs)\nMedication Precertification Request\nPage 3 of 5\n(All fields must be completed and return both pages for precertification review.)\n\nFor Medicare Advantage Part B:\nFor other lines of business:\nPlease use commercial form.\nNote: Riabni and Rituxan are non-\npreferred. The preferred biosimilar\nproducts are Ruxience and Truxima.\nFor rheumatoid arthritis, all Rituxan and\nbiosimilar products are non-preferred.\n\nPatient First Name\nPatient Last Name\nPatient Phone\nPatient DOB\n\nG. CLINICAL INFORMATION (Continued) - Required clinical information must be completed for ALL precertification requests.\nFor Initiation Requests continued (clinical documentation required for all requests):\n\u2610 No Has the patient had a trial and failure of any of the following? (If yes, select all that apply)\n\u2610 \u2610 Inflectra (infliximab-dyyb) \u2610 Renflexis (infliximab-abda) \u2610 Simponi Aria (golimumab)\n\u2610 When was the member's trial and failure of the preferred drug?\n\u2610 Please describe the nature of the failure of the preferred drug\n\u2610 No Has the patient had an adverse reaction to any of the following? (If yes, select all that apply)\n\u2610 \u2610 Inflectra (infliximab-dyyb) \u2610 Renflexis (infliximab-abda) \u2610 Simponi Aria (golimumab)\n\u2610 When was the member's adverse reaction to the preferred drug?\n\u2610 Please describe the nature of the adverse reaction to the preferred drug\n\u2610 No Has the patient had a trial and failure of any of the following? (If yes, select all that apply)\n\u2610 \u2610 Enbrel (etanercept) \u2610 Humira (adalimumab) \u2610 Idacio (adalimumab-aacf) \u2610 Rinvoq (upadacitinib) \u2610 Tyenne SC (tocilizumab-aazg)\n\u2610 Xeljanz/Xeljanz XR (tofacitinib)\n\u2610 When was the member's trial and failure of the preferred drug?\n\u2610 Please describe the nature of the failure of the preferred drug\n\u2610 No Has the patient had a trial and failure of any of the following? (If yes, select all that apply)\n\u2610 \u2610 Enbrel (etanercept) \u2610 Humira (adalimumab) \u2610 Idacio (adalimumab-aacf) \u2610 Rinvoq (upadacitinib) \u2610 Tyenne SC (tocilizumab-aazg)\n\u2610 Xeljanz/Xeljanz XR (tofacitinib)\n\u2610 When was the member's adverse reaction to the preferred drug?\n\u2610 Please describe the nature of the adverse reaction to the preferred drug\nPlease explain if there are any contraindications or other medical reason(s) that the patient cannot use any of the following preferred products when indicated for\nthe patient's diagnosis? (select all that apply)\n\u2610 Inflectra (infliximab-dyyb) \u2610 Renflexis (infliximab-abda) \u2610 Simponi Aria (golimumab)\n\nPlease explain if there are contraindications or any other medical reason(s) that the patient cannot use any of the following preferred products when indicated for\nthe patient's diagnosis? (select all that apply)\n\u2610 Enbrel (etanercept) \u2610 Humira (adalimumab) \u2610 Idacio (adalimumab-aacf) \u2610 Rinvoq (upadacitinib) \u2610 Tyenne SC (tocilizumab-aazg)\n\u2610 Xeljanz/Xeljanz XR (tofacitinib)\n\nFor All Requests (clinical documentation required for all requests):\n\u2610 Yes \u2610 No Will Rituxan (rituximab) be used concomitantly with apremilast, tofacitinib, or other biologic DMARDs (e.g., adalimumab, infliximab)?\nAcute lymphoid leukemia\n\u2610 Yes \u2610 No Does the patient have a documented diagnosis of Philadelphia chromosome-negative acute lymphoid leukemia (ALL)?\n\u2610 Yes \u2610 No Is Rituxan (rituximab) being used as induction/consolidation therapy?\nAutoimmune hemolytic anemia\n\u2610 Yes \u2610 No Does the patient have a documented diagnosis of refractory autoimmune hemolytic anemia?\nAnti-neutrophil cytoplasmic antibody-associated (ANCA-associated) vasculitides\nPlease indicate which of the following applies to the patient: \u2610 Wegener granulomatosis \u2610 Churg-Strauss syndrome\n\u2610 Microscopic polyangiitis \u2610 pauci-immune glomerulonephritis\n\u2610 Yes \u2610 No Will Rituxan (rituximab) be given in conjunction with glucocorticoids?\nAutoimmune blistering diseases, corticosteroid-refractory\n\u2610 Yes \u2610 No Does the patient have a documented diagnosis of corticosteroid-refractory autoimmune blistering disease?\n\u2610 Please select which applies to the patient: \u2610 pemphigus vulgaris \u2610 pemphigus folliaceus \u2610 bullous pemphigoid \u2610 cicatricial pemphigoid\n\u2610 epidermolysis bullosa acquisita \u2610 paraneoplastic pemphigus \u2610 None of the above\nB-cell lymphomas\nPlease select which applies to the patient: \u2610 AIDS-related B-cell lymphoma \u2610 Burkitt lymphoma \u2610 Diffuse large B-cell lymphoma \u2610 Follicular lymphoma\n\u2610 Gastric MALT lymphoma \u2610 High-grade B-Cell lymphoma \u2610 Mantle cell lymphoma\n\u2610 Nodal marginal zone lymphoma \u2610 Nongastric MALT lymphoma \u2610 Primary cutaneous B-cell lymphomas\n\u2610 Splenic marginal zone lymphoma \u2610 Other:\nContinued on next page",
      "images": [],
      "dimensions": {
        "dpi": 200,
        "height": 2200,
        "width": 1700
      }
    },
    {
      "index": 3,
      "markdown": "# MEDICARE FORM\nRiabni\u00ae (rituximab-arrx),\nRituxan\u00ae (rituximab), Ruxience\n(rituximab-pvvr), Truxima (rituximab-abbs)\nMedication Precertification Request\nPage 4 of 5\n(All fields must be completed and return both pages for precertification review.)\n\nFor Medicare Advantage Part B:\nFor other lines of business:\nPlease use commercial form.\nNote: Riabni and Rituxan are non-\npreferred. The preferred biosimilar\nproducts are Ruxience and Truxima.\nFor rheumatoid arthritis, all Rituxan and\nbiosimilar products are non-preferred.\n\nPatient First Name\nPatient Last Name\nPatient Phone\nPatient DOB\n\nG. CLINICAL INFORMATION (Continued) - Required clinical information must be completed for ALL precertification requests.\nCastleman's disease\n[ ] Yes [ ] No Does the patient have a documented diagnosis of multicentric Castleman's disease (angiofollicular lymph node hyperplasia)?\nCentral nervous system lymphomas\nPlease select which applies to the patient: [ ] leptomeningeal metastases from lymphoma [ ] primary CNS lymphoma [ ] none of the above\nChronic or small lymphocytic leukemia\nPlease select which applies to the patient: [ ] chronic lymphocytic leukemia (CLL) [ ] small lymphocytic leukemia [ ] none of the above\nCryoglobulinemia\n[ ] Yes [ ] No Does the patient have a documented diagnosis of cryoglobulinemia?\n[ ] Yes [ ] No Is there clinical documentation that the treatment with corticosteroids and other immunosuppressive agents was ineffective?\nGraft versus host disease, chronic\n[ ] Yes [ ] No Is there a documentation that Rituxan (rituximab) being used as last-resort treatment for chronic graft versus host disease (GVHD)?\nHairy cell leukemia\nPlease select which applies to the patient: [ ] relapsed hairy cell leukemia [ ] refractory hairy cell leukemia [ ] none of the above\nHeart and solid organ transplant\n[ ] Yes [ ] No Is there a documentation that Rituxan (rituximab) is being used for treatment or prevention (desensitization) of highly sensitized patients with\nantibody mediated rejection in heart transplant recipients and other solid organ transplant recipients?\n[ ] Please select which applies to the patient: [ ] heart transplant recipient [ ] other solid organ transplant recipient\nImmune checkpoint-inhibitor related encephalitis\nPlease identify which immune check-point inhibitor caused the encephalitis: [ ] Bavencio (avelumab) [ ] Imfinzi (durvalumab) [ ] Keytruda (pembrolizumab)\n[ ] Opdivo (nivolumab) [ ] Tecentriq (atezolizumab) [ ] Yervoy (ipilimumab)\n[ ] Other: _____________________________________________________________________________________________________________________________________________________________________\nImmune or idiopathic thrombocytopenic purpura\n[ ] Yes [ ] No Does the patient have a documented diagnosis of refractory immune or idiopathic thrombocytopenic purpura (ITP)?\n[ ] [ ] refractory immune thrombocytopenic purpura [ ] idiopathic thrombocytopenic purpura (ITP)\nKidney transplant, rejection prophylaxis\n[ ] Yes [ ] No Is Rituxan (rituximab) being used as rejection prophylaxis in sensitized kidney transplant recipients with donor specific antibodies?\nLymphocyte-predominant Hodgkin's lymphoma\n[ ] Yes [ ] No Does the patient have a documented diagnosis of lymphocyte-predominant Hodgkin's lymphoma?\nMultiple Sclerosis\nPlease indicate the type of multiple sclerosis the patient has been diagnosed with:\n[ ] Relapsing-remitting MS (RRMS) [ ] Secondary-progressive MS (SPMS) [ ] Primary-progressive MS (PPMS) [ ] Progressive-relapsing MS (PRMS)\n[ ] Yes [ ] No Has the patient discontinued other medications used for treating MS (not including Ampyra)?\nMyasthenia gravis (MuSk-MG)\n[ ] Yes [ ] No Does the patient have a documented diagnosis of muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG)?\n[ ] Yes [ ] No Has the patient had an unsatisfactory response to initial immunotherapy?\nNeuromyelitis optica (Devic's disease)\n[ ] Yes [ ] No Does the patient have a documented diagnosis of neuromyelitis optica (Devic's disease)?\n[ ] Yes [ ] No Was the treatment with at least one immunotherapy ineffective?\nOpsoclonus-myoclonus-ataxia (opsoclonus myoclonus syndrome)\n[ ] Yes [ ] No Does the patient have a documented diagnosis of opsoclonus-myoclonus-ataxia (OMA) associated with neuroblastoma?\n[ ] Yes [ ] No Is the patient refractory to steroids, chemotherapy and intravenous immunoglobulins?\n[ ] Please provide the names and date ranges of medications tried:\nMedication: _________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________",
      "images": [],
      "dimensions": {
        "dpi": 200,
        "height": 2200,
        "width": 1700
      }
    },
    {
      "index": 4,
      "markdown": "# MEDICARE FORM\nRiabni\u00ae (rituximab-arrx),\nRituxan\u00ae (rituximab), Ruxience\n(rituximab-pvvr), Truxima (rituximab-abbs)\nMedication Precertification Request\n\nFor Medicare Advantage Part B:\nFor other lines of business:\nPlease use commercial form.\n\nNote: Riabni and Rituxan are non-\npreferred. The preferred biosimilar\nproducts are Ruxience and Truxima.\nFor rheumatoid arthritis, all Rituxan and\nbiosimilar products are non-preferred.\n\nPage 5 of 5\n(All fields must be completed and return both pages for precertification review.)\n\nPatient First Name Patient Last Name Patient Phone Patient DOB\n\nG. CLINICAL INFORMATION (Continued) - Required clinical information must be completed for ALL precertification requests.\n\nRheumatoid Arthritis\nPlease indicate the severity of the patient's rheumatoid arthritis: \u2610 Mild \u2610 Moderate \u2610 Severe\n\u2610 Yes \u2610 No Is there evidence that the disease is active?\n\u2610 Yes \u2610 No Will Rituxan (rituximab) be used in combination with methotrexate?\n\u2194\u2610 Yes \u2610 No Was treatment with methotrexate ineffective, not tolerated or contraindicated?\n\u2194\u2610 Please select: \u2610 ineffective \u2610 not tolerated \u2610 contraindicated\n\u2610 Yes \u2610 No Was treatment with another conventional DMARD ineffective?\n\u2194\u2610 Please select: \u2610 azathioprine \u2610 cyclosporine \u2610 hydroxychloroquine \u2610 leflunomide \u2610 sulfasalazine\n\nSj\u00f6gren syndrome\n\u2610 Yes \u2610 No Does the patient have a documented diagnosis of Sj\u00f6gren's syndrome?\n\u2610 Yes \u2610 No Was treatment with corticosteroids and other immunosuppressive agents ineffective?\n\u2194\u2610 Please provide the names and dates of the corticosteroids and other immunosuppressive agents used:\nMedication: Dates: / / /\nMedication: Dates: / / /\nThrombotic thrombocytopenic purpura\n\u2610 Yes \u2610 No Does the patient have a documented diagnosis of refractory thrombotic thrombocytopenic purpura (TTP)?\n\nWaldenstrom's macroglobulinemia\n\u2610 Yes \u2610 No Does the patient have a documented diagnosis of Waldenstr\u00f6m macroglobulinemia?\n\nFor Continuation Requests:\n\u2610 Yes \u2610 No Is this continuation request a result of the patient receiving samples of Rituxan (rituximab)?\nPlease indicate the length of time on Rituxan (rituximab): _________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________",
      "images": [],
      "dimensions": {
        "dpi": 200,
        "height": 2200,
        "width": 1700
      }
    }
  ]
}